DexCom, Inc. (NASDAQ: DXCM) has announced preliminary financial results for the fourth quarter of 2024, reporting an 8% increase in revenues. The healthcare technology company also provided guidance for fiscal 2025.
As per estimates, in the final three months of fiscal 2024, the company’s revenues rose 8% year-over-year to around $1.113 billionUS revenue is expected to be around $803 million, representing a 4% annual growth; the estimated International revenue is about $310 million, up 17%For fiscal 2025, the management anticipates revenues of $4.60 billion, which reflects an estimated 14% growth from last yearThe top line is expected to benefit from sensor volume growth driven by increasing CGM access and awareness for people with diabetes, the continued rollout of Stelo, further international expansion, and overall market dynamicsAdjusted gross profit margin is expected to be in the range of 64% to 65% in FY25; the guidance for full-year adjusted operating margin is approximately 21%Dexcom is scheduled to report its final audited fourth-quarter and fiscal 2024 results on February 13, 2025, after the closing bell
The post Earnings Summary: DexCom reports preliminary Q4 2024 results first appeared on AlphaStreet.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
